PFE - Valneva Q4: Resilient Pipeline And Partnership With Pfizer Reinforcing A Promising Future
2023-03-29 22:56:19 ET
Summary
- Valneva's pipeline and high-stakes clinical catalysts warrant a buy rating, despite the setback in its Lyme disease Phase 3 trial.
- The CHIKV vaccine candidate is on track for PDUFA in August 2023, and the company plans to launch one or two programs in clinical trials by the close of 2023.
- Valneva's partnership with Pfizer on its Lyme disease vaccine candidate gives the product credibility and commercial potential.
- Clinical and regulatory risks, capital raise risk, commercial and competitive risks, and financial stability are potential risks investors should consider.
For further details see:
Valneva Q4: Resilient Pipeline And Partnership With Pfizer, Reinforcing A Promising Future